IMS 2186 is an anti-choroidal neovascularization agent.1 It inhibits proliferation of NIH3T3 mouse and IMR-90 human fibroblasts (IC50s = 0.5-3 µM), as well as in a panel of eight human cancer cell lines, including ovarian, lung, colon, and pancreatic cancer cells (IC50s = 0.3-3 µM). IMS 2186 (10 µM) decreases migration of THP-1 macrophages in wound healing and chamber assays. Subcutaneous administration of IMS 2186 (20 µg/animal) inhibits VEGF-induced blood vessel formation in a MatrigelTM plug assay in mice. It reduces ocular leakage, as well as cellular proliferation and infiltration in a rat model of laser-induced choroidal neovascularization when administered intravitreally at a dose of 100 µg/eye.
1.Falkenstein, I.A., Cheng, L., Wong-Staal, F., et al.Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186Curr. Eye Res.33(7)599-609(2008)